INCY250117P80000
- 7.60
- 0.000.00%
Incyte Newsroom
Incyte Corp. Stock Rises Tuesday, Still Underperforms Market
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Wells Fargo Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $70
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Incyte Price Target Raised to $70 From $68 at Wells Fargo
The Analyst Verdict: Incyte In The Eyes Of 15 Experts
Wells Fargo Adjusts Incyte's Price Target to $70 From $68, Keeps Equalweight Rating
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Incyte (INCY) and Bicycle Therapeutics (BCYC)
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today
Incyte Analyst Ratings
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock
UBS Initiates Incyte(INCY.US) With Hold Rating, Announces Target Price $77
Express News | Incyte : UBS Initiates Coverage With Neutral Rating; Target Price $77
Incyte to Present at Upcoming Investor Conference
JMP Securities Maintains Incyte(INCY.US) With Hold Rating
Incyte's Mixed Clinical Results and Financial Challenges Lead to Hold Rating
Another Week, Another Index Record | Lkive Stock